Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 1 937.5 JPY -0.13% Market Closed
Market Cap: 254.7B JPY

Relative Value

The Relative Value of one Sawai Group Holdings Co Ltd stock under the Base Case scenario is 2 044.48 JPY. Compared to the current market price of 1 937.5 JPY, Sawai Group Holdings Co Ltd is Undervalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2 044.48 JPY
Undervaluation 5%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
23
vs Industry
60
Median 3Y
0.9
Median 5Y
0.9
Industry
2.4
Forward
1.3
vs History
61
vs Industry
37
Median 3Y
10.3
Median 5Y
11.3
Industry
20.5
Forward
8.5
vs History
55
vs Industry
39
Median 3Y
11.1
Median 5Y
9.4
Industry
15.4
vs History
23
vs Industry
10
Median 3Y
-9.5
Median 5Y
19.3
Industry
22.8
vs History
30
vs Industry
51
Median 3Y
0.9
Median 5Y
1
Industry
1.9
vs History
23
vs Industry
56
Median 3Y
1
Median 5Y
0.9
Industry
2.5
Forward
1.5
vs History
23
vs Industry
37
Median 3Y
3.4
Median 5Y
2.9
Industry
4.9
vs History
28
vs Industry
37
Median 3Y
6
Median 5Y
5.3
Industry
12.4
Forward
6.8
vs History
23
vs Industry
31
Median 3Y
10.6
Median 5Y
9.5
Industry
15.5
Forward
10.5
vs History
52
vs Industry
36
Median 3Y
12.2
Median 5Y
10.4
Industry
14
vs History
14
vs Industry
5
Median 3Y
-11.9
Median 5Y
-8.9
Industry
17.9
vs History
34
vs Industry
53
Median 3Y
0.7
Median 5Y
0.7
Industry
1.8

Multiples Across Competitors

Competitors Multiples
Sawai Group Holdings Co Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Sawai Group Holdings Co Ltd
TSE:4887
254.7B JPY 1.4 9.9 7.5 12.6
US
Eli Lilly and Co
NYSE:LLY
699.5B USD 15.5 66.1 38.5 42.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.8B USD 4.2 26.2 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 19 12.5 14.3
CH
Roche Holding AG
SIX:ROG
208.7B CHF 3.6 18.2 10.2 12.1
UK
AstraZeneca PLC
LSE:AZN
167.6B GBP 4 30.7 126.3 192.8
CH
Novartis AG
SIX:NOVN
186.3B CHF 4.2 18.3 11.1 14.2
US
Merck & Co Inc
NYSE:MRK
206.3B USD 3.2 12.1 8.2 9.7
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
119.8B EUR 2.7 20.9 9.1 13.3
P/E Multiple
Earnings Growth PEG
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average P/E: 24.6
9.9
22%
0.5
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.2
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
19
19%
1
CH
Roche Holding AG
SIX:ROG
18.2
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.7
36%
0.9
CH
Novartis AG
SIX:NOVN
18.3
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
20.9
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBITDA: 394.7
7.5
10%
0.7
US
Eli Lilly and Co
NYSE:LLY
38.5
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
15%
0.8
CH
Roche Holding AG
SIX:ROG
10.2
8%
1.3
UK
AstraZeneca PLC
LSE:AZN
126.3
9%
14
CH
Novartis AG
SIX:NOVN
11.1
5%
2.2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
7%
1.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBIT: 1 698.3
12.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.5
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
16%
0.9
CH
Roche Holding AG
SIX:ROG
12.1
9%
1.3
UK
AstraZeneca PLC
LSE:AZN
192.8
21%
9.2
CH
Novartis AG
SIX:NOVN
14.2
8%
1.8
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
13.3
14%
0.9